A New Approach for the Management of CAD Patients

Project Overview

What is TIMELY?

TIMELY is an EU-funded project. It started in January 2021 and will last up until March 2025.

What is the objective of TIMELY?

The objective is to develop and implement a platform that provides AI-powered apps and dashboards and decision support tools assisting patients and clinicians to personalize healthcare based on risk evaluation, outcome prediction and tailored interventions. The platform will be developed based on a functional platform for interoperability with electronic health records and security mechanisms, to ensure information completeness and continuity and to simplify data sharing. AI in TIMELY, built with big retrospective datasets of >23.000 CAD patients, will constantly monitor and evaluate risks and will indicate any deviation from defined therapy goals or unfavorable changes as well as propose proper interventions.

What is the main hypothesis?


The main hypothesis in the patient-centered TIMELY pathway is that a modular, collaborative eHealth platform, supported by Artificial Intelligence (AI) for the continuous and in-time prediction of cardiac risks and complications and the induction of targeted behavioural change interventions, can be effective and cost-efficient for the secondary prevention of coronary artery disease (CAD) by limiting the physiological and psychological effects of the disease and improving risk factor and symptom management.

"Coronary artery disease (CAD) is a chronic disease that requires life-long care. We believe that assisted self-management of CAD can help to improve patents’ quality of live and improve health-related outcomes. TIMELY was created for continuous and individual patient support based on the latest advances in remote care management."

Dr. Boris Schmitz, Principal Investigator Clinical Study

Tasks @TIMELY

  • Lead partner: Universität Witten/Herdecke

    The overall objective is to deploy a living lab in UWH (Klinik Königsfeld) for the iterative codesign of the end platform towards patient activation and provision of efficient preventive cardiology. Within this WP, the prospective study with 300 patients will be run.

  • Lead partner: Foundation for Research and Technology (FORTH)

    Within this WP all the method and models for the automated evaluation of patients risks with Artificial Intelligence will be developed. Refinement and extension of the already validated for secondary prevention CoroPredict is also foreseen.

  • Lead partner: University of Amsterdam

    TIMELY will develop and evaluate AI, lifestyle interventions with conversational (chatbots), context aware and reinforcement learning agents, for all core components of CR: nutritional counselling, smoking, psychosocial interventions, and physical activity counselling and exercise training.

  • Lead partner: SEMDATEX

    The design of the platform based on the requirements gathered in the Living Lab setting will provide a solid, but “live” specifications and architecture definition for the subsequent implementation of the modules and their integration in TIMELY Net.

  • Lead partner: Tilburg University

    The objective is to implement and to evaluate the TIMELY interventions developed in WP1 through WP4 using randomized controlled trial.

  • Lead partner: BIOTRONIK

    The goal is to increase awareness for the project and its results amongst different stakeholders and to draft an exploitation and market access strategy.

  • Lead partner: University Amsterdam

    Project Management will be concentrated in handling the progress of actual work made in the project, as well as in financial and internal communication issues.